Systematic review of amifostine for the management of oral mucositis in cancer patients

Supportive Care in Cancer

Volumn 21, Issue 1, 2013, Pages 357-364

  Nicolatou Galitis, Ourania ^a   Sarri, Triantafyllia ^a   Bowen, Joanne ^b   Di Palma, Mario ^c   Kouloulias, Vassilios E ^d   Niscola, Pasquale ^e   Riesenbeck, Dorothea ^f   Stokman, Monique ^g   Tissing, Wim ^g   Yeoh, Eric ^b,h   Elad, Sharon ⁱ   Lalla, Rajesh V ^j  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e S EUGENIO HOSPITAL   (Italy)

^f Radiation Oncology Practice   (Germany)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

more..

Author keywords

Amifostine; Guidelines; Oral mucositis; Systematic review

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; MOUTHWASH; PLACEBO;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; ORAL MUCOSITIS; PRACTICE GUIDELINE; PREVENTION STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING;

ADMINISTRATION, TOPICAL; AMIFOSTINE; EVIDENCE-BASED MEDICINE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIATION-PROTECTIVE AGENTS; STOMATITIS;

EID: 84874110209     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1613-6     Document Type: Review

References (44)

1. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995-2025
2. Capizzi RL (1999) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26(2 Suppl 7):3-21
3. Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2:479-489
4. Buntzel J, Kuttner K, Frohlich D, Glatzel M (1998) Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9:505-509
5. Buntzel J, Schuth J, Kuttner K, Glatzel M (1998) Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6:155-160
6. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345
7. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N (2002) Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747
8. Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, Pissakas G, Kolitsi G, Kyprianou K, Kouloulias V, Papanikolaou I, Yiotakis I, Dardoufas K (2003) Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncol 39:397-401
9. Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T (2003) Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft 179:385-389
10. Karacetin D, Yucel B, Leblebicioglu B, Aksakal O, Maral O, Incekara O (2004) A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer. J BUON 9:23-26
11. Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R (2004) The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 31(6 Suppl 18):2-7
12. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V (2005) Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985-990
13. Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, Tesavibul C, Swangsilpa T, Khorprasert C, Shotelersuk K, Kongthanarat Y, Panichevaluk A, Chiewvit S, Pusuwan P, Aekmahachai M, Ratchadara S, Sirilipoche S, Saengsuda Y (2006) Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J Medic AssThail Chotmaihet thangphaet 89:2056-2067
14. Schuchter LM, Hensley ML, Meropol NJ, Winer EP (2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clinic Oncol 20:2895-2903
15. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clinical Oncol 27:127-145
16. Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B, Wibault P, Eschwege F (2000) A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46:1105-1108
17. Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M, Lucesole M, Brunori M, Massidda D, Offidani M, Leoni P, Olivieri A (2000) Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Brit J Haem 110:300-307
18. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulias V (2000) Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clinic Oncol 18:2226-2233
19. Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C (2001) A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Brit J Cancer 84:313-320
20. Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P, Hequet O, Espinouse D, Salles G, Roy P, Eljaafari-Corbin A, Du Manoir-Baumgarten C, Coiffier B (2002) Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 30:769-775
21. Kouloulias VE, Kouvaris JR, Kokakis JD, Kostakopoulos A, Mallas E, Metafa A, Vlahos LJ (2004) Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis. Int J Radiat Oncol Biol Phys 59:1148-1156
22. Gabriel DA, Shea TC, Serody JS, Moore DT, Kirby SL, Harvey D, Krasnov C (2005) Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant 11:1022-1030
23. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K (2005) Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 35:971-977
24. Tsavaris N, Kosmas C, Vadiaka M, Zonios D, Papalambros E, Papantoniou N, Margaris H, Zografos G, Rokana S, Retalis G, Koufos C (2003) Amifostine, in a reduced dose, protects against severe diarrhoea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: A pilot study. JPain Symptom Manage 26:849-854
25. Chauncey TR, Gooley TA, Lloid ME, Schubert MM, Lilleby K, Holmberg L, Bensinger WI (2000) Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Amer J Clinic Oncol 23:406-411
26. Jantunen E, Kuittinen T, Nousiainen T (2002) A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. Leuk Lymphoma 43:1961-1965
27. Benesch M, McDonald GB, Schubert M, Appelbaum FR, Deeg HJ (2003) Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Bone Marrow Transplant 32:1071-1075
28. Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, Uges DR, Hospers GA (2004) Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Res 24(5B):3263-3267
29. Abitbol A, Abdel-Wahab M, Harvey M, Lewin A, Troner M, Hamilton-Nelson K, Wu J, Markoe A (2005) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Amer J Clinic Oncol 28:449-455
30. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64:684-691
31. Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB (2009) Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 115:4514-4523
32. Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG (2006) Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 85:690-700
33. Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T (2010) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (12):CD000978
34. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026-2046
35. Bensadoun RJ, Schubert MM, Lalla RV, Keefe D (2006) Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 14:566-572
36. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820-831
37. Somerfield MR, McCrae RR (2000) Stress and coping research. Methodological challenges, theoretical advances, and clinical applications. Amer Psychol 55:620-625
38. Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clinic Epidem 49:749-754
39. Trog D, Bank P, Wendt TG, Koscielny S, Beleites E (1999) Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft 175:444-449
40. Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC, Chow H, Tan KW, Wong C, Tan CH, Goh YT (2004) A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 34:51-56
41. Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche P, Azria D, Mirimanoff RO, Zouhair A (2006) Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryn Head Neck Surg 132:141-145
42. Anne PR, Machtay M, Rosenthal DI, Brizel DM, Morrison WH, Irwin DH, Chougule PB, Estopinal NC, Berson A, Curran WJ Jr (2007) A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 67:445-452
43. Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O (2007) Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 69:1361-1368
44. Koukourakis MI, Tsoutsou PG, Karpouzis A, Tsiarkatsi M, Karapantzos I, Daniilidis V, Kouskoukis C (2010) Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 77:9-15